257 related articles for article (PubMed ID: 19788418)
1. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.
Gillings AS; Balmanno K; Wiggins CM; Johnson M; Cook SJ
FEBS J; 2009 Nov; 276(21):6050-62. PubMed ID: 19788418
[TBL] [Abstract][Full Text] [Related]
2. Tumour cell survival signalling by the ERK1/2 pathway.
Balmanno K; Cook SJ
Cell Death Differ; 2009 Mar; 16(3):368-77. PubMed ID: 18846109
[TBL] [Abstract][Full Text] [Related]
3. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte autophagy is linked to C/EBP-homologous protein, Bcl2-interacting mediator of cell death, and BH3-interacting domain death agonist gene expression.
Zhang J; Singh N; Robinson-Taylor KS; Dorsett-Martin WA; Morris MW; Earl TM; Anderson CD
J Surg Res; 2015 May; 195(2):588-95. PubMed ID: 25772147
[TBL] [Abstract][Full Text] [Related]
6. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway.
Craxton A; Draves KE; Gruppi A; Clark EA
J Exp Med; 2005 Nov; 202(10):1363-74. PubMed ID: 16301744
[TBL] [Abstract][Full Text] [Related]
7. Growth-factor-dependent phosphorylation of Bim in mitosis.
Grãos M; Almeida AD; Chatterjee S
Biochem J; 2005 May; 388(Pt 1):185-94. PubMed ID: 15651977
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
9. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels.
Ewings KE; Wiggins CM; Cook SJ
Cell Cycle; 2007 Sep; 6(18):2236-40. PubMed ID: 17881896
[TBL] [Abstract][Full Text] [Related]
10. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
11. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
Sheridan C; Brumatti G; Martin SJ
J Biol Chem; 2008 Aug; 283(32):22128-35. PubMed ID: 18508762
[TBL] [Abstract][Full Text] [Related]
13. Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.
Chalmers CJ; Balmanno K; Hadfield K; Ley R; Cook SJ
Biochem J; 2003 Oct; 375(Pt 1):99-109. PubMed ID: 12844349
[TBL] [Abstract][Full Text] [Related]
14. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Boisvert-Adamo K; Aplin AE
Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
[TBL] [Abstract][Full Text] [Related]
15. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
[TBL] [Abstract][Full Text] [Related]
16. Bim regulates BCR-induced entry of B cells into the cell cycle.
Craxton A; Draves KE; Clark EA
Eur J Immunol; 2007 Oct; 37(10):2715-22. PubMed ID: 17705137
[TBL] [Abstract][Full Text] [Related]
17. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.
Erlacher M; Labi V; Manzl C; Böck G; Tzankov A; Häcker G; Michalak E; Strasser A; Villunger A
J Exp Med; 2006 Dec; 203(13):2939-51. PubMed ID: 17178918
[TBL] [Abstract][Full Text] [Related]
18. A Critical role for Bim in retinal ganglion cell death.
McKernan DP; Cotter TG
J Neurochem; 2007 Aug; 102(3):922-30. PubMed ID: 17442051
[TBL] [Abstract][Full Text] [Related]
19. The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.
Greenhough A; Wallam CA; Hicks DJ; Moorghen M; Williams AC; Paraskeva C
Oncogene; 2010 Jun; 29(23):3398-410. PubMed ID: 20348947
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
